Neutralizing antibodies directed against the influenza hemagglutinin head domain are more potent in vivo than those directed against the broadly conserved stem domain
Sanofi Pasteur is developing Universal Influenza Vaccine (UIV) strategies to address breadth of vaccine coverage and increased efficacy against drifted strains. Influenza vaccines designed to preferentially elicit…

